Table 1.

NAMPT inhibitors in clinical trials.

Ph	Drug	Type	Condition	ClinicalTrials.gov Identifier	Treatment	Name of the Study
II	FK866	Non- competitive	Melanoma	NCT00432107	Alone	Study to Assess APO866 for the Treatment of Advanced Melanoma (2006, completed)
			Cutaneous T-cell Lymphoma	NCT00431912	Alone	Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma (2007, completed)
			B-cell Chronic Lymphocytic Leukemia	NCT00435084	Alone	Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL (2007, completed)
I	GMX1778/CHS-828	Oral competitive	Solid tumors	NCT00003979	Alone	CHS 828 in Treating Patients with Solid Tumors (1999, Withdrawn)
I	OT-82	Oral	Relapsed or refractory lymphoma	NCT03921879	Dose escalation and expansion	Safety and Efficacy of OT-82 in Participants with Relapsed or Refractory Lymphoma (2019, recruiting)
I	KPT-9274/ATG-019	Non- competitive oral dual inhibitor of PAK4 and NAMPT	Solid tumors, non-Hodgkin’s lymphoma	NCT02702492	Alone or co-administered with Niacin or Nivolumab	PAK4 and NAMPT in Patients with Solid Malignancies or Non-Hodgkin’s Lymphoma (2016, terminated)
			Solid tumors, non-Hodgkin’s lymphoma	NCT04281420	Alone or co-administered with Niacin	Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin’s Lymphoma (2020, recruiting)
			Acute Myeloid Leukemia	NCT04914845	Alone	KPT-9274 in Patients with Relapsed and Refractory Acute Myeloid Leukemia (2021, recruiting)

Ph: clinical phase.